The acceptance of Bristol Myers Squibb's application by the FDA is a positive development, indicating progress in the drug's approval process. This could potentially lead to a new treatment option in the market, enhancing the company's product portfolio and possibly boosting investor confidence. The setting of a Prescription Drug User Fee Act goal date provides a clear timeline for the review process, which is generally viewed positively by the market.